Ignite Creation Date:
2024-05-06 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05728268
Status:
RECRUITING
Last Update Posted:
2023-02-15
First Post:
2023-02-04
Brief Title:
Neoadjuvant Dose-dense Chemotherapy for HRHER2- Breast Cancer Patients With High Proliferation Index
Sponsor:
Shantou Central Hospital
Organization:
Shantou Central Hospital
Study Overview
Official Title:
Neoadjuvant Dose-dense Chemotherapy for HRHER2- Breast Cancer Patients With High Proliferation Index
Status:
RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Studies have shown that dose-dense chemotherapy reduces the risk of recurrence and death of breast cancer patients comparing with standard-schedule chemotherapy But some research data indicate that HRHER2- breast cancer patients benefit from dose-dense chemotherapy while some have negative results How to identify HRHER2 breast cancer patients who are more likely to benefit from dose-dense chemotherapy is strongly necessary Ki67 is a marker reflecting the proliferation of tumor cells Breast cancer patients with high Ki67 are more likely to benefit from dose-dense chemotherapy The purpose of this project is to investigate the efficacy and safety of neoadjuvant dose-dense chemotherapy for HRHER2- breast cancer patients with high proliferation index At the same time we will explore biomarkers such as MammaPrint and BluePrint to further identify patients who benefit more from neoadjuvant dose-dense chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None